ÂÜÀòÂÒÂ×

Daniel Geffken is the Founder and Managing Director of Danforth Advisors, a firm established in August 2011 that collaborates with life science companies to optimize their financial and operational outcomes. In addition to leading Danforth Advisors, Daniel holds multiple roles in interim and advisory capacities at various pharmaceutical companies, including serving as the Interim Chief Financial Officer at Eloxx Pharmaceuticals and CalciMedica, and as a Senior Financial Advisor for Olaris, Inc., Affini-T, Myeloid Therapeutics, and Century Therapeutics, among others. Daniel's educational background includes an MBA from Harvard Business School and a B.S. in Economics from The Wharton School.